A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances

References

• Bourne RRA, Flaxman SR, Braithwaite T, et al.; Vision Loss Expert Group. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(9):e888–e897.
   PubMed Web of Science ®Google Scholar
• Varela-Fernandez R, Diaz-Tome V, Luaces-Rodriguez A, et al. Drug delivery to the posterior segment of the eye: biopharmaceutic and pharmacokinetic considerations. Pharmaceutics. 2020;12(3):269.
   Web of Science ®Google Scholar
• Edelhauser HF, Rowe-Rendleman CL, Robinson MR, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010;51(11):5403–5420.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Kakkar S. Nanotherapy for posterior eye diseases. J Control Release. 2014;193:100–112.
   PubMed Web of Science ®Google Scholar
• Sampata KM, Garg SJ . Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21:178–183.
   PubMed Web of Science ®Google Scholar
• Suri R, Beg S, Kohli K. Target strategies for drug delivery bypassing ocular barriers. J Drug Deliv Sci Technol. 2020;55:101389.
   Web of Science ®Google Scholar
• Nayak K, Misra M. A review on recent drug delivery systems for posterior segment of eye. Biomed Pharmacother. 2018;107:1564–1582.
   PubMed Web of Science ®Google Scholar
• Enriquez de Salamanca A, Diebold Y, Calonge M, et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci. 2006;47(4):1416–1425.
   PubMed Web of Science ®Google Scholar
• Johannsdottir S, Jansook P, Stefansson E, et al. Topical drug delivery to the posterior segment of the eye: dexamethasone concentrations in various eye tissues after topical administration for up to 15 days to rabbits. J Drug Deliv Sci Technol. 2018;45:449–454.
   Web of Science ®Google Scholar
• Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87(12):1479–1488.
   PubMed Web of Science ®Google Scholar
• Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Investig Ophthalmol Vis Sci. 2000;41(5):1181–1185.
   PubMed Web of Science ®Google Scholar
• Pitkanen L, Ranta VP, Moilanen H, et al. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci. 2005;46(2):641–646.
   PubMed Web of Science ®Google Scholar
• Thakur A, Kadam RS, Kompella UB. Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids. Drug Metab Dispos. 2011;39(5):771–781.
   PubMed Web of Science ®Google Scholar
• Mannermaa E, Reinisalo M, Ranta VP, et al. Filter-cultured ARPE-19 cells as outer blood-retinal barrier model. Eur J Pharm Sci. 2010;40(4):289–296. 11
   PubMed Web of Science ®Google Scholar
• Imperiale JC, Acosta GB, Sosnik A. Polymer-based carriers for ophthalmic drug delivery. J Control Release. 2018;285:106–141.
   PubMed Web of Science ®Google Scholar
• Sugrue MF. The pharmacology of antiglaucoma drugs. Pharmacol Ther. 1989;43(1):91–138.
   PubMed Web of Science ®Google Scholar
• Lakhani P, Patil A, Majumdar S. Recent advances in topical nano drug-delivery systems for the anterior ocular segment. Ther Deliv. 2018;9(2):137–153.
   PubMed Web of Science ®Google Scholar
• Del Amo EM, Rimpela AK, Heikkinen E, et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2017;57:134–185.
   PubMed Web of Science ®Google Scholar
• Robinson MR, Lee SS, Kim H, et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res. 2006;82(3):479–487.
   PubMed Web of Science ®Google Scholar
• Li J, Lan B, Li X, et al. Effect of intraocular pressure (IOP) and choroidal circulation on controlled episcleral drug delivery to retina/vitreous. J Control Release. 2016;243:78–85.
   PubMed Web of Science ®Google Scholar
• Amrite AC, Edelhauser HF, Singh SR, et al. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis. 2008;14:150–160.
   PubMed Web of Science ®Google Scholar
• Al-Ghananeem AM, Crooks PA. Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery. Molecules. 2007;12(3):373–388.
   PubMed Web of Science ®Google Scholar
• Nakano M, Lockhart CM, Kelly EJ, et al. Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition. Drug Metab Rev. 2014;46(3):247–260.
   PubMed Web of Science ®Google Scholar
• Argikar UA, Dumouchel JL, Dunne CE, et al. Ocular non-P450 oxidative, reductive, hydrolytic, and conjugative drug metabolizing enzymes. Drug Metab Rev. 2017;49(3):372–394.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Garg A, Singla AK, et al. Vesicular systems in ocular drug delivery: an overview. Int J Pharm. 2004;269(1):1–14.
   PubMed Web of Science ®Google Scholar
• Verstraelen J, Reichl S. Expression analysis of MDR1, BCRP and MRP3 transporter proteins in different in vitro and ex vivo cornea models for drug absorption studies. Int J Pharm. 2013;441(1-2):765–775.
   PubMedGoogle Scholar
• Becker U, Ehrhardt C, Daum N, et al. Expression of ABC-transporters in human corneal tissue and the transformed cell line, HCE-T. J Ocul Pharmacol Ther. 2007;23(2):172–181.
   PubMed Web of Science ®Google Scholar
• Vellonen KS, Hellinen L, Mannermaa E, et al. Expression, activity and pharmacokinetic impact of ocular transporters. Adv Drug Deliv Rev. 2018;126:3–22.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou L, Fang L, et al. Multifunctional carboxymethyl chitosan derivatives-layered double hydroxide hybrid nanocomposites for efficient drug delivery to the posterior segment of the eye. Acta Biomater. 2020;104:104–114.
   PubMed Web of Science ®Google Scholar
• Asasutjarit R, Managit C, Phanaksri T, et al. Formulation development and in vitro evaluation of transferrin-conjugated liposomes as a carrier of ganciclovir targeting the retina. Int J Pharm. 2020;577:119084.
   PubMed Web of Science ®Google Scholar
• Martens TF, Remaut K, Deschout H, et al. Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy. J Control Release. 2015;202:83–92.
   PubMed Web of Science ®Google Scholar
• Suen WL, Chau Y. Specific uptake of folate-decorated triamcinolone-encapsulating nanoparticles by retinal pigment epithelium cells enhances and prolongs antiangiogenic activity. J Control Release. 2013;167(1):21–28.
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz J. The blood-ocular barriers. Surv Ophthalmol. 1979;23(5):279–296.
   PubMed Web of Science ®Google Scholar
• Freddo TF. A contemporary concept of the blood-aqueous barrier. Prog Retin Eye Res. 2013;32:181–195.
   PubMed Web of Science ®Google Scholar
• Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res. 2008;27(6):622–647.
   PubMed Web of Science ®Google Scholar
• Brockhaus L, Goldblum D, Eggenschwiler L, et al. Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics. Clin Microbiol Infect. 2019;25(11):1364–1369.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu X, Gu Y, et al. Recent advance of nanoparticle-based topical drug delivery to the posterior segment of the eye. Expert Opin Drug Deliv. 2018;15(7):687–701.
   PubMed Web of Science ®Google Scholar
• Thakur SS, Barnett NL, Donaldson MJ, et al. Intravitreal drug delivery in retinal disease: are we out of our depth? Expert Opin Drug Deliv. 2014;11(10):1575–1590.
   PubMed Web of Science ®Google Scholar
• Waite D, Wang Y, Jones D, et al. Posterior drug delivery via periocular route: challenges and opportunities. Ther Deliv. 2017;8(8):685–699.
   PubMed Web of Science ®Google Scholar
• Jung JH, Chae JJ, Prausnitz MR. Targeting drug delivery within the suprachoroidal space. Drug Discov Today. 2019;24(8):1654–1659.
   PubMed Web of Science ®Google Scholar
• Hughes PM, Olejnik O, Chang-Lin JE, et al. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005;57(14):2010–2032.
   PubMed Web of Science ®Google Scholar
• Djebli N, Khier S, Griguer F, et al. Ocular drug distribution after topical administration: population pharmacokinetic model in rabbits. Eur J Drug Metab Pharmacokinet. 2017;42(1):59–68.
   PubMed Web of Science ®Google Scholar
• Kompella UB, Amrite AC, Pacha Ravi R, et al. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res. 2013;36:172–198.
   PubMed Web of Science ®Google Scholar
• Gao JQ, Lv Q, Li LM, et al. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes. Biomaterials. 2013;34(22):5628–5639.
   PubMed Web of Science ®Google Scholar
• Sarao V, Veritti D, Boscia F, et al. Intravitreal steroids for the treatment of retinal diseases. Scientif World J. 2014;2014:989501.
   Web of Science ®Google Scholar
• Shah SS, Denham LV, Elison JR, et al. Drug delivery to the posterior segment of the eye for pharmacologic therapy. Expert Rev Ophthalmol. 2010;15(1):75–93.
   PubMedGoogle Scholar
• Elsaid N, Jackson TL, Elsaid Z, et al. PLGA microparticles entrapping chitosan-based nanoparticles for the ocular delivery of ranibizumab. Mol Pharm. 2016;13(9):2923–2940.
   PubMed Web of Science ®Google Scholar
• Jiang P, Chaparro FJ, Cuddington CT, et al. Injectable biodegradable bi-layered capsule for sustained delivery of bevacizumab in treating wet age-related macular degeneration. J Control Release. 2020;320:442–456.
   PubMed Web of Science ®Google Scholar
• Ranta VP, Mannermaa E, Lummepuro K, et al. Barrier analysis of periocular drug delivery to the posterior segment. J Control Release. 2010;148(1):42–48.
   PubMed Web of Science ®Google Scholar
• Ghate D, Brooks W, McCarey BE, et al. Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci. 2007;48(5):2230–2237.
   PubMed Web of Science ®Google Scholar
• Shome D, Kalita D, Jain V, et al. Carboplatin loaded polymethylmethacrylate nano-particles in an adjunctive role in retinoblastoma: an animal trial. Indian J Ophthalmol. 2014;62(5):585–589.
   PubMed Web of Science ®Google Scholar
• Jung JH, Chiang B, Grossniklaus HE, et al. Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle. J Control Release. 2018;277:14–22.
   PubMed Web of Science ®Google Scholar
• You Q, Sokolov M, Grigartzik L, et al. How nanoparticle physicochemical parameters affect drug delivery to cells in the retina via systemic interactions. Mol Pharm. 2019;16(12):5068–5075.
   PubMedGoogle Scholar
• Li J, Xue Y, Tian J, et al. Fluorinated-functionalized hyaluronic acid nanoparticles for enhanced photodynamic therapy of ocular choroidal melanoma by ameliorating hypoxia. Carbohydr Polym. 2020;237:116119.
   PubMed Web of Science ®Google Scholar
• Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 2018;103:598–613.
   PubMed Web of Science ®Google Scholar
• Yadav M, Schiavone N, Guzman-Aranguez A, et al. Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed treatment option for age-related macular degeneration (AMD). Drug Deliv Transl Res. 2020;10(4):919–944.
   PubMed Web of Science ®Google Scholar
• Tabatabaei SN, Derbali RM, Yang C, et al. Co-delivery of miR-181a and melphalan by lipid nanoparticles for treatment of seeded retinoblastoma. J Control Release. 2019;298:177–185.
   PubMed Web of Science ®Google Scholar
• Patel S, Ryals RC, Weller KK, et al. Lipid nanoparticles for delivery of messenger RNA to the back of the eye. J Control Release. 2019;303:91–100.
   PubMed Web of Science ®Google Scholar
• Himawan E, Ekstrom P, Buzgo M, et al. Drug delivery to retinal photoreceptors. Drug Discov Today. 2019;24(8):1637–1643.
   PubMed Web of Science ®Google Scholar
• Doktorovova S, Kovacevic AB, Garcia ML, et al. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: current evidence from in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2016;108:235–252.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee A, Das PJ, Adhikari P, et al. Novel drug delivery systems for ocular therapy: with special reference to liposomal ocular delivery. Eur J Ophthalmol. 2019;29(1):113–126.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Iezhitsa I, Agarwal P, et al. Liposomes in topical ophthalmic drug delivery: an update. Drug Deliv. 2016;23(4):1075–1091.
   PubMed Web of Science ®Google Scholar
• Blazaki S, Pachis K, Tzatzarakis M, et al. Novel liposome aggregate platform (LAP) system for sustained retention of drugs in the posterior ocular segment following intravitreal injection. Int J Pharm. 2020;576:118987.
   PubMedGoogle Scholar
• Pachis K, Blazaki S, Tzatzarakis M, et al. Sustained release of intravitreal flurbiprofen from a novel drug-in-liposome-in-hydrogel formulation. Eur J Pharm Sci. 2017;109:324–333.
   PubMed Web of Science ®Google Scholar
• Khalil M, Hashmi U, Riaz R, et al. Chitosan coated liposomes (CCL) containing triamcinolone acetonide for sustained delivery: a potential topical treatment for posterior segment diseases. Int J Biol Macromol. 2020;143:483–491.
   PubMed Web of Science ®Google Scholar
• Cheng T, Li J, Cheng Y, et al. Triamcinolone acetonide-chitosan coated liposomes efficiently treated retinal edema as eye drops. Exp Eye Res. 2019;188:107805.
   PubMed Web of Science ®Google Scholar
• Lai S, Wei Y, Wu Q, et al. Liposomes for effective drug delivery to the ocular posterior chamber. J Nanobiotechnology. 2019;17(1):64.
   PubMed Web of Science ®Google Scholar
• Mu H, Wang Y, Chu Y, et al. Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization. Drug Deliv. 2018;25(1):1372–1383.
   PubMed Web of Science ®Google Scholar
• Zhang R, Qian J, Li X, et al. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes. Br J Ophthalmol. 2017;101(12):1731–1738.
   PubMed Web of Science ®Google Scholar
• Lee J, Goh U, Lee HJ, et al. Effective retinal penetration of lipophilic and lipid-conjugated hydrophilic agents delivered by engineered liposomes. Mol Pharm. 2017;14(2):423–430.
   PubMedGoogle Scholar
• Platania CBM, Fisichella V, Fidilio A, et al. Topical ocular delivery of TGF-beta1 to the back of the eye: implications in age-related neurodegenerative diseases. Int J Mol Sci. 2017;18(10):2076.
   Web of Science ®Google Scholar
• Li J, Cheng T, Tian Q, et al. A more efficient ocular delivery system of triamcinolone acetonide as eye drop to the posterior segment of the eye. Drug Deliv. 2019;26(1):188–198.
   PubMed Web of Science ®Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, et al. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(4):12.
   PubMed Web of Science ®Google Scholar
• Lajunen T, Nurmi R, Kontturi L, et al. Light activated liposomes: functionality and prospects in ocular drug delivery. J Control Release. 2016;244(Pt B):157–166.
   PubMedGoogle Scholar
• Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13(3-4):144–151.
   PubMed Web of Science ®Google Scholar
• Nagarwal RC, Kant S, Singh PN, et al. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release. 2009;136(1):2–13.
   PubMed Web of Science ®Google Scholar
• Pandit J, Sultana Y, Aqil M. Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation. Artif Cells Nanomed Biotechnol. 2017;45(7):1397–1407.
   PubMed Web of Science ®Google Scholar
• Chittasupho C, Posritong P, Ariyawong P. Stability, cytotoxicity, and retinal pigment epithelial cell binding of hyaluronic acid-coated PLGA nanoparticles encapsulating lutein. AAPS PharmSciTech. 2018;20(1):4.
   PubMed Web of Science ®Google Scholar
• Li F, Wen Y, Zhang Y, et al. Characterisation of 2-HP-β-cyclodextrin-PLGA nanoparticle complexes for potential use as ocular drug delivery vehicles. Artif Cells Nanomed Biotechnol. 2019;47(1):4097–4108.
   PubMed Web of Science ®Google Scholar
• Luo L, Yang J, Oh Y, et al. Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis. J Control Release. 2019;296:68–80.
   PubMed Web of Science ®Google Scholar
• Qiu F, Meng T, Chen Q, et al. Fenofibrate-loaded biodegradable nanoparticles for the treatment of experimental diabetic retinopathy and neovascular age-related macular degeneration. Mol Pharm. 2019;16(5):1958–1970.
   PubMedGoogle Scholar
• Wang Y, Liu CH, Ji T, et al. Intravenous treatment of choroidal neovascularization by photo-targeted nanoparticles. Nat Commun. 2019;10(1):804.
   PubMedGoogle Scholar
• Meng T, Kulkarni V, Simmers R, et al. Therapeutic implications of nanomedicine for ocular drug delivery. Drug Discov Today. 2019;24(8):1524–1538.
   PubMed Web of Science ®Google Scholar
• Singh Y, Meher JG, Raval K, et al. Nanoemulsion: concepts, development and applications in drug delivery. J Control Release. 2017;252:28–49.
   PubMed Web of Science ®Google Scholar
• Daull P, Lallemand F, Garrigue JS. Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. J Pharm Pharmacol. 2014;66(4):531–541.
   PubMed Web of Science ®Google Scholar
• Hegde RR, Verma A, Ghosh A. Microemulsion: new insights into the ocular drug delivery. ISRN Pharm. 2013;2013:826798.
   PubMedGoogle Scholar
• Jiao J. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv Drug Deliv Rev. 2008;60(15):1663–1673.
   PubMed Web of Science ®Google Scholar
• Singh M, Bharadwaj S, Lee KE, et al. Therapeutic nanoemulsions in ophthalmic drug administration: concept in formulations and characterization techniques for ocular drug delivery. J Control Release. 2020;328:895–916.
   PubMed Web of Science ®Google Scholar
• Ge Y, Zhang A, Sun R, et al. Penetratin-modified lutein nanoemulsion in-situ gel for the treatment of age-related macular degeneration. Expert Opin Drug Deliv. 2020;17(4):603–619.
   PubMed Web of Science ®Google Scholar
• Hagigit T, Abdulrazik M, Orucov F, et al. Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye. J Control Release. 2010;145(3):297–305.
   PubMed Web of Science ®Google Scholar
• Mandal A, Bisht R, Rupenthal ID, et al. Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies. J Control Release. 2017;248:96–116.
   PubMed Web of Science ®Google Scholar
• Pepic I, Lovric J, Filipovic-Grcic J. Polymeric micelles in ocular drug delivery: rationale, strategies and challenges. Chem Biochem Eng Q. 2012;26(4):365–377.
   Web of Science ®Google Scholar
• Sai N, Dong X, Huang P, et al. A novel gel-forming solution based on PEG-DSPE/solutol HS 15 mixed micelles and gellan gum for ophthalmic delivery of curcumin. Molecules. 2019;25(1):81.
   Web of Science ®Google Scholar
• Lin S, Ge C, Wang D, et al. Overcoming the anatomical and physiological barriers in topical eye surface medication using a peptide-decorated polymeric micelle. ACS Appl Mater Interfaces. 2019;11(43):39603–39612.
   PubMed Web of Science ®Google Scholar
• Han H, Yin Q, Tang X, et al. Development of mucoadhesive cationic polypeptide micelles for sustained cabozantinib release and inhibition of corneal neovascularization. J Mater Chem B. 2020;8(23):5143–5154.
   PubMed Web of Science ®Google Scholar
• Grimaudo MA, Pescina S, Padula C, et al. Topical application of polymeric nanomicelles in ophthalmology: a review on research efforts for the noninvasive delivery of ocular therapeutics. Expert Opin Drug Deliv. 2019;16(4):397–413.
   PubMed Web of Science ®Google Scholar
• Xu X, Sun L, Zhou L, et al. Functional chitosan oligosaccharide nanomicelles for topical ocular drug delivery of dexamethasone. Carbohydr Polym. 2020;227:115356.
   PubMed Web of Science ®Google Scholar
• Mandal A, Cholkar K, Khurana V, et al. Topical formulation of self-assembled antiviral prodrug nanomicelles for targeted retinal delivery. Mol Pharm. 2017;14(6):2056–2069.
   PubMed Web of Science ®Google Scholar
• Grimaudo MA, Pescina S, Padula C, et al. Poloxamer 407/TPGS mixed micelles as promising carriers for cyclosporine ocular delivery. Mol Pharm. 2018;15(2):571–584.
   PubMed Web of Science ®Google Scholar
• Mandal A, Gote V, Pal D, et al. Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa®) for Dry Eye Disease . Pharm Res. 2019;36(2):36.
   PubMed Web of Science ®Google Scholar
• Rodríguez Villanueva J, Navarro MG, Rodríguez Villanueva L. Dendrimers as a promising tool in ocular therapeutics: latest advances and perspectives. Int J Pharm. 2016;511(1):359–366.
   PubMed Web of Science ®Google Scholar
• Lyu Z, Ding L, Huang AY-T, et al. Poly(amidoamine) dendrimers: covalent and supramolecular synthesis. Mater Today Chem. 2019;13:34–48.
   Web of Science ®Google Scholar
• Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev. 2005;57(15):2215–2237.
   PubMed Web of Science ®Google Scholar
• Iezzi R, Guru BR, Glybina IV, et al. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials. 2012;33(3):979–988.
   PubMed Web of Science ®Google Scholar
• Yang X, Wang L, Li L, et al. A novel dendrimer-based complex co-modified with cyclic RGD hexapeptide and penetratin for noninvasive targeting and penetration of the ocular posterior segment. Drug Deliv. 2019;26(1):989–1001.
   PubMed Web of Science ®Google Scholar
• Yavuz B, Pehlivan SB, Vural I, et al. In vitro/in vivo evaluation of dexamethasone-PAMAM dendrimer complexes for retinal drug delivery. J Pharm Sci. 2015;104(11):3814–3823.
   PubMed Web of Science ®Google Scholar
• Tai L, Liu C, Jiang K, et al. Noninvasive delivery of oligonucleotide by penetratin-modified polyplexes to inhibit protein expression of intraocular tumor. Nanomedicine. 2017;13(6):2091–2100.
   PubMed Web of Science ®Google Scholar
• Wu LP, Ficker M, Christensen JB, et al. Dendrimers in medicine: therapeutic concepts and pharmaceutical challenges. Bioconjug Chem. 2015;26(7):1198–1211.
   PubMed Web of Science ®Google Scholar
• Chou SJ, Yang P, Ban Q, et al. Dual supramolecular nanoparticle vectors enable CRISPR/Cas9-mediated knockin of retinoschisin 1 gene-A potential nonviral therapeutic solution for X-linked juvenile retinoschisis. Adv Sci (Weinh). 2020;7(10):1903432.
   PubMedGoogle Scholar
• Wang Y, Shahi PK, Xie R, et al. A pH-responsive silica-metal-organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries. J Control Release. 2020;324:194–203.
   PubMed Web of Science ®Google Scholar
• Jiang K, Hu Y, Gao X, et al. Octopus-like flexible vector for noninvasive intraocular delivery of short interfering nucleic acids. Nano Lett. 2019;19(9):6410–6417.
   PubMed Web of Science ®Google Scholar
• Mishra G, Dash B, Pandey S. Layered double hydroxides: a brief review from fundamentals to application as evolving biomaterials. Appl Clay Sci. 2018;153:172–186.
   Web of Science ®Google Scholar
• Gu Y, Xu C, Wang Y, et al. Multifunctional nanocomposites based on liposomes and layered double hydroxides conjugated with glycylsarcosine for efficient topical drug delivery to the posterior segment of the eye. Mol Pharm. 2019;16(7):2845–2857.
   PubMed Web of Science ®Google Scholar
• Cabrera FJ, Wang DC, Reddy K, et al. Challenges and opportunities for drug delivery to the posterior of the eye. Drug Discov Today. 2019;24(8):1679–1684.
   PubMed Web of Science ®Google Scholar
• Rodrigues GA, Lutz D, Shen J, et al. Topical drug delivery to the posterior segment of the eye: addressing the challenge of preclinical to clinical translation. Pharm Res. 2018;35(12):245.
   PubMed Web of Science ®Google Scholar
• Mann BK, Stirland DL, Lee HK, et al. Ocular translational science: a review of development steps and paths. Adv Drug Deliv Rev. 2018;126:195–203.
   PubMed Web of Science ®Google Scholar
• Baum JL, Barza M, Shushan D, et al. Concentration of gentamicin in experimental corneal ulcers. Topical vs subconjunctival therapy. Arch Ophthalmol. 1974;92(4):315–317.
   PubMedGoogle Scholar